Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia.

被引:51
|
作者
Ergun, E
Heinzl, H
Stur, W
机构
[1] Univ Vienna, Sch Med, Dept Ophthalmol, Vienna, Austria
[2] Univ Vienna, Sch Med, Dept Med Comp Sci, Vienna, Austria
关键词
D O I
10.1016/j.ajo.2004.04.055
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To examine the influence of age, lesion size, degree of myopia, and baseline visual acuity on the visual outcome of patients with pathologic myopia and choroidal neovascularization (CNV) who received photodynamic therapy (PDT) with verteporfin. DESIGN: Retrospective, noncomparative consecutive case series. METHODS: Forty-three eyes of 41 patients were treated in a two-year time span; 36 eyes of 36 patients who had received PDT for CNV due to pathologic myopia were examined for the above-mentioned factors 24 months after first treatment. All patients had been treated according to the Verteporfin in Photodynamic Therapy (VIP) study criteria. Patients were examined in two- to three-month intervals with Snellen visual acuity, biomicroscopy, and fluorescein angiography. RESULTS: Baseline visual acuity and age were both prognostic factors for visual outcome (P = .0097, P = .0055). Lesion size (greatest linear dimension) at baseline, refractive error, or the number of treatments had no influence on the outcome. CONCLUSION: Age and baseline visual acuity have an effect on visual outcome in patients receiving PDT due to CNV secondary to pathologic myopia. Younger patients and patients with higher baseline visual acuity had a better treatment outcome. (C) 2004 by Elsevier Inc. All rights reserved.
引用
收藏
页码:434 / 438
页数:5
相关论文
共 50 条
  • [41] Verteporfin photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia: a 12-month retrospective review (vol 18, pg 955, 2008)
    Costagliola, C.
    Campa, C.
    Incorvala, C.
    Parmeggiani, F.
    Menzione, M.
    Della Corte, M.
    Rinaldi, M.
    Romano, M.
    Semeraro, F.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2009, 19 (02) : 329 - 329
  • [42] Treatment of subfoveal choroidal neovascularization secondary to choroidal nevus using photodynamic therapy
    Levy, J
    Shneck, M
    Klemperer, I
    Lifshitz, T
    OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04): : 343 - 345
  • [43] Long-term Results of Photodynamic Therapy for Choroidal Neovascularization in Japanese Patients With Pathologic Myopia
    Hayashi, Kengo
    Ohno-Matsui, Kyoko
    Shimada, Noriaki
    Moriyama, Muka
    Hayashi, Wakako
    Wang, Jiying
    Yoshida, Takeshi
    Tokoro, Takashi
    Mochizuki, Manabu
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 151 (01) : 137 - 147
  • [44] Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: Comparison with nontreated controls
    Hayashi, Kengo
    Ohno-Matsui, Kyoko
    Teramukai, Satoshi
    Shimada, Noriaki
    Moriyama, Muka
    Hara, Wakako
    Yoshida, Takeshi
    Tokoro, Takashi
    Mochizuki, Manabu
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 145 (03) : 518 - 526
  • [45] Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia
    M. Rinaldi
    F. Semeraro
    F. Chiosi
    A. Russo
    M. R. Romano
    M. C. Savastano
    R. dell’Omo
    C. Costagliola
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 529 - 539
  • [46] Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia
    Rinaldi, M.
    Semeraro, F.
    Chiosi, F.
    Russo, A.
    Romano, M. R.
    Savastano, M. C.
    dell'Omo, R.
    Costagliola, C.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (03) : 529 - 539
  • [47] Retinal pigment epithelial marginal retraction after photodynamic therapy for choroidal neovascularization in pathologic myopia
    Pece, A.
    Isola, V.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2008, 18 (05) : 841 - 844
  • [48] Early anatomical outcome in different types of subfoveal choroidal neovascularization treated with photodynamic therapy.
    Zanchi, S
    Gerosa, F
    Massacesi, AL
    Staurenghi, G
    Orzalesi, N
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2001, 42 (04) : S439 - S439
  • [49] Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia
    Hernandez-Rojas, Myriam L.
    Quiroz-Mercado, Hugo
    Dalma-Weiszhausz, Jose
    Fromow-Guerra, Jans
    Amaya-Espinosa, Andres
    Solis-Vivanco, Adriana
    Martinez-Castellanos, Maria Ana
    Aiello, Lloyd P.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (06): : 707 - 712
  • [50] Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin -: 1-year results of a randomized clinical trial -: VIP report no. 1
    Arnold, J
    Kilmartin, D
    Olson, J
    Neville, S
    Robinson, K
    Laird, A
    Richmond, C
    Farrow, A
    McKay, S
    Saperstein, DA
    Aaberg, TM
    Johnson, JB
    Waldron, R
    Loupe, D
    Gillman, J
    Myles, B
    Schachat, AP
    Bressler, NM
    Bressler, SB
    Nesbitt, P
    Porter, T
    Hawse, P
    Hartnett, M
    Eager, A
    Belt, J
    Cain, D
    Emmert, D
    George, T
    Herring, M
    McDonald, J
    Monés, J
    Corcóstegui, B
    Gilbert, M
    Duran, N
    Sisquella, M
    Nolla, A
    Margalef, A
    Miller, JW
    Gragoudas, ES
    Lane, AM
    Emmanuel, N
    Holbrook, A
    Evans, C
    Lord, US
    Walsh, DK
    Callahan, CD
    DuBois, JL
    Lewis, H
    Kaiser, PK
    Holody, LJ
    OPHTHALMOLOGY, 2001, 108 (05) : 841 - 852